G1 Therapeutics Inc Stock News

Nuveen Asset Management LLC lowered its stake in G1 Therapeutics Inc (NASDAQ:GTHX) by 1.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission.

G1 Therapeutics (NASDAQ:GTHX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, Zacks.com reports. According to Zac

G1 Therapeutics (NASDAQ:GTHX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday, Zacks.com reports. The brokerage presently has

Geode Capital Management LLC lifted its stake in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 3.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities

Exane Derivatives bought a new position in shares of G1 Therapeutics Inc (NASDAQ:GTHX) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institut

Alliancebernstein L.P. decreased its holdings in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 5.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities

Bank of New York Mellon Corp boosted its holdings in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 1.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchan

Shares of G1 Therapeutics Inc (NASDAQ:GTHX) have earned a consensus rating of “Buy” from the ten ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst

G1 Therapeutics (NASDAQ:GTHX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday, Zacks.com reports. The firm presently has a $14.0

G1 Therapeutics (NASDAQ:GTHX) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Wednesday, BidAskClub reports. Several other eq

Cubist Systematic Strategies LLC acquired a new position in shares of G1 Therapeutics Inc (NASDAQ:GTHX) during the fourth quarter, according to its most recent disclosure with the Securities and Excha

Goldman Sachs Group Inc. decreased its holdings in G1 Therapeutics Inc (NASDAQ:GTHX) by 32.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Ex

G1 Therapeutics Inc (NASDAQ:GTHX) shares fell 5.3% during trading on Tuesday . The stock traded as low as $10.55 and last traded at $10.61, 635,212 shares were traded during mid-day trading. An increa

G1 Therapeutics (NASDAQ:GTHX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Zacks.com reports. The brokerage curr

RESEARCH TRIANGLE PARK, N.C., April 07, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark.